No profile data available.
Annovis Bio, Inc. (ANVS) is a healthcare company in the brain and nerve treatment drugs industry, based in Malvern, United States, with about 7 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$28.85 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $51.64 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.
Annovis Bio reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$51.64 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Cingulate Inc. (CING), Mira Pharmaceuticals, Inc. (MIRA), Alterity Therapeutics Limited (ATHE), CervoMed Inc. (CRVO).